Cargando…
The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects
Clostridioides difficile infection (CDI) is an urgent threat and unmet medical need. The current treatments for CDI are not enough to fight the burden of CDI and recurrent CDI (r-CDI). This review aims to highlight the future drugs for CDI and their related patented applications. The non-patent lite...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953237/ https://www.ncbi.nlm.nih.gov/pubmed/36830964 http://dx.doi.org/10.3390/biomedicines11020426 |
_version_ | 1784893828404084736 |
---|---|
author | Alshrari, Ahmed S. Hudu, Shuaibu Abdullahi Elmigdadi, Fayig Imran, Mohd. |
author_facet | Alshrari, Ahmed S. Hudu, Shuaibu Abdullahi Elmigdadi, Fayig Imran, Mohd. |
author_sort | Alshrari, Ahmed S. |
collection | PubMed |
description | Clostridioides difficile infection (CDI) is an urgent threat and unmet medical need. The current treatments for CDI are not enough to fight the burden of CDI and recurrent CDI (r-CDI). This review aims to highlight the future drugs for CDI and their related patented applications. The non-patent literature was collected from PubMed and various authentic websites of pharmaceutical industries. The patent literature was collected from free patent databases. Many possible drugs of the future for CDI, with diverse mechanisms of action, are in development in the form of microbiota-modulating agents (e.g., ADS024, CP101, RBX2660, RBX7455, SYN-004, SER-109, VE303, DAV132, MET-2, and BB128), small molecules (e.g., ridinilazole, ibezapolstat, CRS3123, DNV3837, MGB-BP-3, alanyl-L-glutamine, and TNP-2198), antibodies (e.g., IM-01 and LMN-201), and non-toxic strains of CD (e.g., NTCD-M3). The development of some therapeutic agents (e.g., DS-2969b, OPS-2071, cadazolid, misoprostol, ramoplanin, KB109, LFF571, and Ramizol) stopped due to failed clinical trials or unknown reasons. The patent literature reveals some important inventions for the existing treatments of CDI and supports the possibility of developing more and better CDI-treatment-based inventions, including patient-compliant dosage forms, targeted drug delivery, drug combinations of anti-CDI drugs possessing diverse mechanisms of action, probiotic and enzymatic supplements, and vaccines. The current pipeline of anti-CDI medications appears promising. However, it will be fascinating to see how many of the cited are successful in gaining approval from drug regulators such as the US FDA and becoming medicines for CDI and r-CDI. |
format | Online Article Text |
id | pubmed-9953237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99532372023-02-25 The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects Alshrari, Ahmed S. Hudu, Shuaibu Abdullahi Elmigdadi, Fayig Imran, Mohd. Biomedicines Review Clostridioides difficile infection (CDI) is an urgent threat and unmet medical need. The current treatments for CDI are not enough to fight the burden of CDI and recurrent CDI (r-CDI). This review aims to highlight the future drugs for CDI and their related patented applications. The non-patent literature was collected from PubMed and various authentic websites of pharmaceutical industries. The patent literature was collected from free patent databases. Many possible drugs of the future for CDI, with diverse mechanisms of action, are in development in the form of microbiota-modulating agents (e.g., ADS024, CP101, RBX2660, RBX7455, SYN-004, SER-109, VE303, DAV132, MET-2, and BB128), small molecules (e.g., ridinilazole, ibezapolstat, CRS3123, DNV3837, MGB-BP-3, alanyl-L-glutamine, and TNP-2198), antibodies (e.g., IM-01 and LMN-201), and non-toxic strains of CD (e.g., NTCD-M3). The development of some therapeutic agents (e.g., DS-2969b, OPS-2071, cadazolid, misoprostol, ramoplanin, KB109, LFF571, and Ramizol) stopped due to failed clinical trials or unknown reasons. The patent literature reveals some important inventions for the existing treatments of CDI and supports the possibility of developing more and better CDI-treatment-based inventions, including patient-compliant dosage forms, targeted drug delivery, drug combinations of anti-CDI drugs possessing diverse mechanisms of action, probiotic and enzymatic supplements, and vaccines. The current pipeline of anti-CDI medications appears promising. However, it will be fascinating to see how many of the cited are successful in gaining approval from drug regulators such as the US FDA and becoming medicines for CDI and r-CDI. MDPI 2023-02-01 /pmc/articles/PMC9953237/ /pubmed/36830964 http://dx.doi.org/10.3390/biomedicines11020426 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Alshrari, Ahmed S. Hudu, Shuaibu Abdullahi Elmigdadi, Fayig Imran, Mohd. The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects |
title | The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects |
title_full | The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects |
title_fullStr | The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects |
title_full_unstemmed | The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects |
title_short | The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects |
title_sort | urgent threat of clostridioides difficile infection: a glimpse of the drugs of the future, with related patents and prospects |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953237/ https://www.ncbi.nlm.nih.gov/pubmed/36830964 http://dx.doi.org/10.3390/biomedicines11020426 |
work_keys_str_mv | AT alshrariahmeds theurgentthreatofclostridioidesdifficileinfectionaglimpseofthedrugsofthefuturewithrelatedpatentsandprospects AT hudushuaibuabdullahi theurgentthreatofclostridioidesdifficileinfectionaglimpseofthedrugsofthefuturewithrelatedpatentsandprospects AT elmigdadifayig theurgentthreatofclostridioidesdifficileinfectionaglimpseofthedrugsofthefuturewithrelatedpatentsandprospects AT imranmohd theurgentthreatofclostridioidesdifficileinfectionaglimpseofthedrugsofthefuturewithrelatedpatentsandprospects AT alshrariahmeds urgentthreatofclostridioidesdifficileinfectionaglimpseofthedrugsofthefuturewithrelatedpatentsandprospects AT hudushuaibuabdullahi urgentthreatofclostridioidesdifficileinfectionaglimpseofthedrugsofthefuturewithrelatedpatentsandprospects AT elmigdadifayig urgentthreatofclostridioidesdifficileinfectionaglimpseofthedrugsofthefuturewithrelatedpatentsandprospects AT imranmohd urgentthreatofclostridioidesdifficileinfectionaglimpseofthedrugsofthefuturewithrelatedpatentsandprospects |